Skip to main content
. 2022 Sep 28;610(7930):161–172. doi: 10.1038/s41586-022-05192-0

Extended Data Fig. 1. MuFAP-IL2v fails to synergize with muPD-L1 therapy during chronic LCMV infection.

Extended Data Fig. 1

a, Chronically LCMV-infected mice (> day 40 post-infection) were left untreated or treated with muPD-L1, muPD-L1 + muFAP-IL2wt, and muPD-L1 + muFAP-IL2v therapy for 2 weeks and then CD8+ T-cell responses and viral titer were examined. b, Representative FACS plots for DbGP33+ CD8+ T cells in spleen. c, Numbers of DbGP33+ and DbGP276+ CD8+ T cells. d, Phenotypic marker expression on DbGP33+ CD8+ T cells. e, Representative FACS plots for IFN-γ+ and INF-γ+TNF-α+ LCMV-specific CD8+ T cells. f, Numbers of IFN-γ+ and INF-γ+TNF-α+ LCMV-specific CD8+ T cells. g, Viral titer in spleen. Results were pooled from 2-3 experiments with n = 2–5 mice per group in each experiment. Data are presented as geometric mean and 95% CI (c,f) or mean and SD (d,g) with p values. Statistical comparisons were performed using one-way ANOVA with Tukey’s multiple comparison test. Untx, untreated; AF, Alexa Fluor.

Source Data